Translational and clinical development of therapeutic siRNA and ASOs: current industry practices, perspectives, and recommendations
Jesper Kammersgaard Christensen(Novo Nordisk (Denmark)), Vibha Jawa(EpiVax (United States)), Darshana Jani(Bioanalytica (Switzerland)), Jingxian Chen(Biogen (United States)), Amir S. Youssef(Simulation Technologies (United States)), Xien Yu Chua(Alnylam Pharmaceuticals (United States)), Felix Huth(Novartis (Switzerland)), Guangnong Zhang(Novo Nordisk (Denmark)), Shirin Hooshfar(Eli Lilly (United States)), Christophe Husser(Roche (Switzerland)), Barent DuBois(Novo Nordisk (United States)), Katharina Root(Novartis (Switzerland)), Carol Kuo(Takeda (Japan)), Nicholas Colletti(Bristol-Myers Squibb (Germany)), Jeffrey C. Kurz(Alnylam Pharmaceuticals (United States)), Wenying Jian(Johnson & Johnson (United States)), Sara C. Humphreys(Bioanalytica (Switzerland)), V. Ravikanth(Eli Lilly (United States)), Matthew E. Albertolle(Electronic BioSciences (United States)), Helle Linnebjerg(Eli Lilly (United States)), Francis D. Gibbons(AstraZeneca (United States)), Girish R. Chopda(Novo Nordisk (Denmark)), Sumeet Singla(Novartis (Switzerland)), Steve R. Hood(Age UK), Chenxiao Tang(AstraZeneca (South Korea)), Krishna Aluri(Alnylam Pharmaceuticals (United States)), Annie Lumen(National Center for Toxicological Research), Thomas N. Kakuda(Johnson & Johnson (United States)), Steven Zhang(Novo Nordisk (Denmark)), Pedro Morais(ProQR Therapeutics (Netherlands)), Rongrong Jiang(Eisai (Japan)), Sabine Lohmann(Roche (Switzerland)), Tao Niu(Sarepta Therapeutics (United States)), Jing Liu(Gansu University of Traditional Chinese Medicine), Linzhi Chen(Boehringer Ingelheim (Germany)), Shyam Kumar Gudey(Bioanalytica (Switzerland)), Swati Gupta(AbbVie (United States))
Cited by 12
Related Papers
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA
|Cell Research|2011|1.2k
Best practices and benchmarks for intact protein analysis for top-down mass spectrometry
|Nature Methods|2019|389
The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
|Frontiers in Cell and Developmental Biology|2021|264
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113